| Field | Specification |
|---|---|
| Mfr No | |
| Concentration | |
| Formulation | |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| Target |
Overview
This GenCefe mRNA encodes ANG2, a growth factor construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.
mRNA Construct Design
- 5′ Cap: Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1/IFIT3).
- Modified Nucleotides: 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.
- Poly(A) Tail: 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.
- 5′ UTR: hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.
- 3′ UTR: hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.
- Signal Peptide: No
- Protein Tag: No
- Codon Optimisation: No (native human codon usage retained)
- mRNA Length: Provided upon order placement.
- Form: Lyophilised powder; reconstitute in DEPC-treated water as needed.
This mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.
Biological Background
Growth factors are secreted or membrane-bound polypeptides that regulate cell proliferation, survival, differentiation, and migration by binding to specific cell-surface receptors and activating downstream signalling cascades (e.g., MAPK/ERK, PI3K/AKT, JAK/STAT). mRNA-based delivery of growth factors enables transient, dose-controlled protein expression in target cells without the need for stable genomic integration. This approach is particularly relevant for ex vivo cell expansion protocols, stem cell differentiation studies, and functional receptor-ligand binding assays, where precise temporal control of growth factor availability is required.
Research Relevance and Current Trends
- Ex vivo cell manufacturing: Transient mRNA expression of growth factors such as SCF, FLT3L, and TPO is being investigated for short-window stimulation of HSC expansion without chronic cytokine exposure that risks differentiation bias.
- Receptor-ligand interaction studies: Growth factor mRNA provides native-topology ligands for SPR, BLI, and cell-based binding assays validating therapeutic antibody epitopes on receptor ectodomains.
- Tissue engineering scaffolds: Growth factor mRNA is incorporated into hydrogel and scaffold matrices to achieve controlled spatiotemporal protein release in tissue-regeneration models.
Common Research Applications
- Receptor activation assays — transient growth factor mRNA expression stimulates cognate receptors in cell-based reporter assays to characterise ligand-receptor interactions.
- Ex vivo cell expansion — short-duration growth factor mRNA pulses to stimulate haematopoietic or stem cell expansion without chronic cytokine exposure.
- Antibody neutralisation studies — mRNA-expressed secreted growth factors as target antigens in neutralisation bioassays validating anti-growth-factor therapeutic antibodies.
Notes for Experimental Interpretation
- Secreted growth factors expressed from transfected cells are present in conditioned media; ensure downstream assays account for the actual secreted protein concentration rather than mRNA input dose.
- Growth factor receptor expression on the target cell must be confirmed; absence of receptor expression on the transfected cell line may result in undetectable signalling readouts.
- Transient expression windows are typically 24–72 h post-transfection for lyophilised mRNA; titrate dose and time-point empirically for the specific growth factor and cell type.
Synthetic mRNA products typically incorporate chemical modifications to minimize innate immune recognition. The most widely used modification is N1-methylpseudouridine (m1Ψ) substitution at all uridine positions, which reduces activation of Toll-like receptors (TLR7/TLR8) and protein kinase R (PKR), resulting in improved translational efficiency and a reduced inflammatory response. The 5′ cap structure is equally important: Cap1 (m7GpppNm), which includes 2′-O-methylation at the first transcribed nucleotide, closely mimics endogenous mammalian mRNA and limits recognition by innate immune sensors such as IFIT1 and IFIT3. Together, these modifications support more robust and sustained protein expression in research applications.
Synthetic mRNA is highly sensitive to ribonuclease (RNase) degradation and must be handled carefully. Lyophilized products should be stored at −20°C; aqueous formulations should be kept at −70°C or below. Repeated freeze-thaw cycles should be avoided — aliquoting immediately upon receipt is strongly recommended. All handling must be performed in an RNase-free environment using dedicated pipettes, nuclease-free consumables, and DEPC-treated or certified nuclease-free water. RNA integrity should be confirmed by agarose gel electrophoresis or capillary electrophoresis (e.g., Bioanalyzer or Fragment Analyzer) before use in critical experiments, particularly for transfection or in vivo delivery applications.
Linear mRNA and circular RNA (circRNA) differ fundamentally in structure, stability, and translational mechanism. Linear mRNA carries a 5′ cap and poly(A) tail that enable efficient cap-dependent translation by the ribosome; it is ideal for studies requiring rapid, high-level transient protein expression, mRNA delivery research, and immunogen modeling. circRNA lacks free 5′ and 3′ ends, making it inherently resistant to exonucleolytic degradation, which confers substantially greater intracellular stability. Translation of circRNA occurs via internal ribosome entry sites (IRES) or other cap-independent mechanisms. circRNA is particularly valuable for miRNA sponge applications, sustained transgene expression platforms, and studies of RNA stability and function. Choose linear mRNA when fast, high-yield transient expression is needed; choose circRNA when extended intracellular stability, prolonged expression, or sponge-based loss-of-function studies are the priority.
Quality-controlled synthetic mRNA should be characterized by multiple orthogonal analytical methods. Standard assessments include: agarose gel electrophoresis or capillary electrophoresis (Bioanalyzer, Fragment Analyzer) to confirm full-length transcript integrity; HPLC to assess purity and residual double-stranded RNA (dsRNA) content; UV spectrophotometry for concentration and A260/A280 ratio; and optionally LC-MS for sequence and modification verification. A Certificate of Analysis (CoA) should accompany each lot, documenting yield, purity, integrity score, and endotoxin level (LAL assay) for products used in cell-based or animal studies. Functional activity is further confirmed by in vitro transfection followed by protein detection (e.g., flow cytometry, Western blot, or luminescence assay), confirming translational competence of the final product.
Synthetic mRNA can be delivered into cells and organisms through several established modalities. For in vitro applications, lipid-based transfection reagents (lipofection), electroporation, and polymer-based nanoparticles are the most common approaches. Lipid nanoparticles (LNPs) are the gold-standard delivery system and support high transfection efficiency both in vitro and in vivo. For in vivo studies, intramuscular, intravenous, intratumoral, or intraperitoneal administration may be used depending on the target tissue and research objective; the choice of delivery vehicle (LNP, polymeric carrier, or direct injection) should be matched to the organ of interest and application. Delivery efficiency is influenced by mRNA modifications, concentration, formulation composition, and cell type; optimization experiments are recommended for each new experimental system before scaling.
Can't find the mRNA or circRNA construct you need? We offer custom synthesis and add-on services to help you move your project forward — from sequence design and codon optimization to custom mRNA synthesis and circular RNA (circRNA) production for both in vitro and in vivo applications. Options may include chemically modified mRNA (e.g., N1-methylpseudouridine substitution, Cap1 capping strategy), circRNA synthesis via chemical ligation (short segments ≤100 nt) or IVT-based cyclization (longer constructs ≥200 nt), HPLC purification, and full QC documentation including gel or Bioanalyzer integrity analysis and a Certificate of Analysis. Additional options may include multiple synthesis scales from small research batches to larger quantities, miRNA sponge circRNA constructs, IRES element selection for cap-independent circRNA translation, labels and conjugation, and delivery formulation guidance. We can also assist with negative and scramble control formats and related RNA tools when a catalog product does not meet your specifications. Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
